neck cancer News
-
Curasight expands its strategy and strengthen its position as a theranostic company
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company. With reference to the ...
By Curasight
-
Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet and using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/34857658/). The phase II study The phase II trial (NCT02965001) aimed to ...
By Curasight
-
Galera Announces Plan to Submit Avasopasem NDA by Year End
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA) for avasopasem manganese (avasopasem) for the treatment of radiotherapy-induced severe oral mucositis ...
-
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The ...
By Transgene
-
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis ...
-
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection. The prospective series was conducted at the University Hospitals Cleveland Medical ...
By Isoray Inc.
-
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck cancers HOOKIPA ...
-
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented in an oral presentation at the upcoming ...
-
CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
-
Pioneering VeraForm® in Head and Neck Cancer Treatment: Sarcomatoid Carcinoma Tumor Bed Marking
Head and neck cancer surgery presents a number of unique challenges, not only for the surgeon but for the radiation oncologist who will subsequently treat those patients. Great care with an emphasis on precision must be taken to ensure that critical structures and tissues avoid collateral damage when possible. However, given the surgical site often lies in soft tissue, exact identification of the ...
-
GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients with Head and Neck Cancer
DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) that may benefit from treatment beyond typical surgical ...
-
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021. Poster ...
-
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapy Phase 2 to proceed with alternating 2-vector therapy in combination with pembrolizumab, which will help inform the randomized Phase 2 trial with pembrolizumab planned to start in the first half of 2023 Additional Phase 2 cohort will ...
-
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy: Relevant neoantigens could be identified in all evaluable patients and TG4050 induced tumor specific T cell responses against multiple of these patient-specific neoantigen targets. Early signs of clinical activity were observed with ...
By Transgene
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
`It was a life saver`: New London developed device for feeding tube insertions is a world first
Researchers in London, Ont., are the first in the world to use a new device for feeding tube insertion that can improve patient safety and reduce the cost of health-care services. A team from Lawson Health Research Institute has partnered with CoapTech LLC, a medical device company, to study the use of the PUMA-G System. In October of last year, the medical and research teams were the first in ...
By CoapTech
-
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live ...
-
TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021. The session, “New Era in Biologically-Targeted ...
-
TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam System for High-Precision Boron Neutron Capture Therapy
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with BEC GmbH (BEC) to incorporate a customized, robotic patient positioning system as part of its Alphabeam™ Neutron System for the high-precision radiation treatment of tumors. During BNCT, it is essential that the ...
-
Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for bio-technology industry, recently announced the release of new measles virus antigens suitable for both IgM and IgG detection. These new products are intended for research use only and are not diagnostic use. Measles virus (MeV) is a negative-sense RNA virus with a non-segmented genome and lipid envelope ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you